Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PhOx 430

Next Previous
X
Search
Drug Profile

PhOx 430

Alternative Names: PhO-430; PhOx-430

Latest Information Update: 23 Aug 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phost'in Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Glucosyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Aug 2022 Phost'In Therapeutics conducts a pre-IND meeting with the US FDA (Phost'In Therapeutics pipeline, August 2022)
  • 18 Jul 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (PO) (NCT05495295)
  • 07 Jun 2022 French National Agency for the Safety of Medicines and Health Products (ANSM) and the Italian Medicines Agency (AIFA) accepted the CTA application for a phase I/II trial in Solid tumours

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top